CGMP/Finished Pharmaceuticals/Adulterated
Similar Posts
Bruce G. Rankin, DO. DeLand, FL. EIR issued 11/24/2020
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 11/24/2020
Short Title (70 char) Bruce G. Rankin, DO. DeLand, FL. EIR issued 11/24/2020
FEI Number 3006528394
Firm Name Bruce G. Rankin, DO
Record Type EIR
State FL
Establishment Type Clinical InvestigationsFukuzyu Pharmaceutical Co., Ltd. – 1/19/2024
Fukuzyu Pharmaceutical Co., Ltd. – 1/19/2024. Country: Japan. Record Type: 483FDA requires expanded labeling about weight loss risk in patients younger than 6 years taking extended-release stimulants for ADHD
The U.S. Food and Drug Administration (FDA) is revising the labeling of all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder (ADHD) – including certain formulations of amphetamine and methylphenidate – to warn about the risk of weight loss and other adverse reaCDER SBIA On-Demand Learning Library
FDA’s CDER Small Business and Industry Assistance (SBIA) is making available our YouTube learning library – now hundreds of our recordings are readily accessible.Alembic Pharmaceuticals Limited – 11/10/2021
Alembic Pharmaceuticals Limited – 11/10/2021. Country: India. Record Type: 483Olympus Announces Voluntary Corrective Action for the Single-Use Ligating Device
Center Valley, Pa., (December 5, 2025)-Olympus Corporation today announced a voluntary medical device corrective action for its Single-Use Ligating Device (“Polyloop”) following identification of a potential safety issue.